NEW DRUG APPROVALS BY FDA
DA Approves Stendra for Erectile
Dysfunction
4/30/2012
The FDA has approved
Vivus’s Stendra (avanafil), a phosphodiesterase type 5 (PDE5)
inhibitor, indicated for the treatment of erectile dysfunction.Stendra will
be available in 50, 100, and 200 mg tablets, with a recommended starting dose
for most patients of 100 mg taken 30 minutes prior to sexual activity. Stendra should
not be taken more than once daily and should not be coadministered with
nitrates because a sudden drop in blood pressure may occur.
FDA
Approves Dymista
The FDA has approved Meda's Dymista nasal
spray for the treatment of seasonal allergic rhinitis in patients 12 years and
older who require treatment with both azelastine hydrochloride and fluticasone
propionate for symptomatic relief.
FDA
Approves Elelyso
The FDA has approved Pfizer's Elelyso (taliglucerase
alfa) for injection, an enzyme replacement therapy for the long-term treatment
of adults with type 1 Gaucher disease.
Fabior Foam
The FDA has approved Stiefel's Fabior (tazarotene)
0.1% foam for the treatment of acne vulgaris in patients 12 years of age and
older.
Pertzye
The FDA has approved Digestive Care's Pertzye (pancrelipase)
delayed-release capsules for treatment of exocrine pancreatic insufficiency
caused by cystic fibrosis or other conditions. The Pertzye formulation
was previously marketed under the trade name Pancrecarb MS-16 .
Generic Requip XL Approved
Actavis has received FDA approval of the first
generic equivalent to GlaxoSmithKline's Requip XL (ropinirole) extended-release tablets
2, 4, 6, 8, and 12 mg. Ropinirole extended release is indicated for the
treatment of the signs and symptoms of idiopathic Parkinson disease.
Generic Plavix
The FDA has approved generic versions of drug Plavix (clopidogrel
bisulfate), indicated for the treatment of acute coronary syndrome, recent
myocardial infarction, recent stroke, or established peripheral arterial
disease. Clopidogrel must be dispensed with a patient Medication Guide ... Read more
Generic Viramune Available
Roxane Laboratories has announced the immediate
availability of generic Viramune (nevirapine) tablets and oral
suspension. Nevirapine is indicated for use in combination with other
antiretroviral agents for the treatment of HIV-1 infection.
Butoconazole
Nitrate 2% Vaginal Cream
The FDA has approved Perrigo's butoconazole
nitrate 2% vaginal cream, the generic equivalent of KV Pharmaceutical's Gynazole-1, indicated for the local treatment of
vulvovaginal candidiasis. The product is expected to launch by the end of 2012.
Generic Delsym
The FDA has granted approval to Perrigo Company
and Tris Pharma for an abbreviated new drug application for the generic
equivalent to Reckitt Benckiser's Delsym (dextromethorphan polistirex)
extended-release oral suspension. Dextromethorphan is indicated for the
temporary ... Read more
Absorica
The FDA has approved Cipher Pharmaceuticals' Absorica (isotretinoin)
for the treatment of severe recalcitrant nodular acne. Absorica is
expected to be launched in the US in late 2012.
Perjeta for Treatment of Breast Cancer
The FDA has approved Roche's Perjeta (pertuzumab),
a humanized monoclonal antibody, for the treatment of human epidermal growth
factor receptor 2 (HER2)–positive late-stage (metastatic) breast cancer. Perjeta is
intended for patients who have not received prior treatment for ... Read more
MenHibrix Vaccine
The FDA has approved GlaxoSmithKline's MenHibrix (meningococcal
groups C and Y and Haemophilus b tetanus toxoid conjugate vaccine),
indicated to prevent invasive disease caused by Neisseria meningitidisserogroups C and Y and Haemophilus influenzae type
b. MenHibrix is
approved for use in children aged 6 weeks through 18 months.
Belviq for Weight Loss
The FDA has approved Arena Pharmaceuticals' and
Eisai's Belviq (lorcaserin hydrochloride), indicated
as an adjunct to a reduced-calorie diet and increased physical activity for
chronic weight management in adult patients with an initial body mass index
(BMI) of 30 kg/m2 or greater ... Read more
Generic Detrol Tablets Approved
The FDA has approved Teva Pharmaceuticals' generic
equivalent to Pfizer's Detrol (tolterodine tartrate) tablets 1 and
2 mg. Tolterodine tartrate is indicated for treatment of overactive bladder
with symptoms of urinary frequency, urgency, or urge incontinence.
FDA
Approves Generic Duac Gel
The FDA has approved Perrigo's clindamycin phosphate
1.2%/benzoyl peroxide 5% topical gel, the generic equivalent of Stiefel
Laboratories' Duac gel. Duac gel is
indicated for the topical treatment of inflammatory acne vulgaris. Perrigo has
commenced shipment of the product.
NEW INDICATIONS
Afinitor
The FDA has approved Afinitor (everolimus)
for the treatment of noncancerous kidney tumors (renal angiomyolipomas) not
requiring immediate surgery in patients with tuberous sclerosis complex (TSC). Afinitor is
also indicated for the treatment of progressive neuroendocrine tumors ... Read more
Votrient
The FDA has approved GlaxoSmithKline's Votrient (pazopanib)
to treat patients with advanced soft tissue sarcoma who have previously
received chemotherapy. Votrient was previously granted orphan drug
status for this new indication. Pazopanib is also indicated for the treatment
of ... Read more
Levaquin Approved to Treat Plague
The FDA has approved Janssen Pharmaceuticals' Levaquin (levofloxacin)
to treat patients with plague, a rare and potentially deadly bacterial
infection, as well as for use in reducing the risk of contracting plague after
exposure toYersinia pestis, the bacterium that causes the disease ... Read more
Expanded Levemir Pediatric Indication
The FDA has approved expanded labeling for Novo
Nordisk's Levemir (insulin detemir [rDNA origin]
injection) to include children 2 to 5 years of age with type 1 diabetes.
Insulin determir is now approved for glycemic control in patients from age 2
years through adulthood with type 1 diabetes and in adults with type 2 diabetes.
Durezol
The FDA has approved Alcon Vision's Durezol (difluprednate
ophthalmic emulsion) 0.05% for the treatment of endogenous anterior uveitis. Durezol is
also indicated for the treatment of inflammation and pain associated with
ocular surgery.
Atripla Approved for Pediatric Use
The FDA has approved Atripla (efavirenz/emtricitabine/ tenofovir
disoproxil fumarate) tablets for use in pediatric patients 12 years and older. Atripla was
previously indicated in adults for use alone as a complete regimen or in
combination with other antiretroviral agents for the treatment of HIV-1
infection. ... Read more
Lyrica
The FDA has approved Pfizer's Lyrica (pregabalin)
capsules for the management of neuropathic pain associated with spinal cord
injury. Lyrica received priority review for this new
indication. Lyrica was previously indicated for the
management of fibromyalgia; for the management of ... Read more
DRUG RECALLS
Imodium Multi-Symptom Relief Recall
McNeil has informed its wholesale customers in the
US that it is voluntarily recalling 1 lot (CMF023, found on the side of the
product box) of the 18-caplet package size of Imodium Multi-Symptom Relief(loperamide/simethicone)
due to a packaging issue. The product is being recalled at the wholesale level
only, not from consumers or store shelves ... Read more
Advil Liqui-Gels Recalled
Pfizer has recalled several lots of Advil Liqui-Gels 200 mg
(ibuprofen), 40 count, 40+20 count, and 240 count bottles due to a stronger
odor caused by increased enzymatic hydrolysis time for the gelatin
manufacturing process ... Read more
Franck's
Compounded Preparations Recall
The FDA is notifying all health care providers and
medical care organizations who have ordered sterile compounded products from
Franck's Compounding Pharmacy of Ocala, FL, of a recall due to a possible lack
of sterility. ... Read more
Introvale Oral Contraceptive Recalled
Sandoz announced a voluntary recall of 10 lots of
its generic oral contraceptive Introvale (levonorgestrel/ethinyl estradiol
tablets), distributed in the United States between January 2011 and May 2012.
The recall was issued after a reported packaging flaw in which the white
placebo tablets were mistakenly in the ninth row of ... Read more
FDA
Recalls Wellesse Digestive 3-in-1 Supplement
The FDA has issued a recall of select lots of
Botanical Laboratories' Wellesse Digestive 3-in-1
Health liquid dietary supplement. Affected
lots were distributed in the US after May 1, 2012, and include the 16 oz size
with "LOT 34441C (followed by a 4-digit time code) A EXP 03/2014" jet
... Read more
Merck
Issues Voluntary Recall of M-M-R II
Merck announced a voluntary recall of one lot
(0851AA) of M-M-R II (measles, mumps, and rubella virus
vaccine, live) because of an inadvertent shipment of doses to US customers
between May 17, 2012 and May 25, 2012, prior to final internal approval for
market release ... Read more
OTHER DRUG NEWS
Victrelis Interactions Warning
The FDA is notifying the public that Victrelis (boceprevir), a
hepatitis C virus (HCV) protease inhibitor, should not be coadministered with
certain ritonavir-boosted HIV protease inhibitors because of the possibility of
reduced effectiveness of HCV or HIV treatment. Ritonavir-boosted ... Read more
Zortress Black Box Warning Revised
The FDA has approved a revised black box warning
for Zortress (everolimus)
noting that increased mortality was observed in a heart transplant clinical
trial and that use in heart transplantation is not recommended. Zortress is
indicated for the prophylaxis of organ rejection in adult patients at low to
moderate immunologic risk receiving a kidney transplant.
Lexiva Pediatric Dosing Expanded
The FDA has approved expanded dosing
recommendations for use of GlaxoSmithKline's Lexiva (fosamprenavir) oral suspension in
pediatric patients; the label now includes dosing for pediatric patients 4
weeks to 18 years of age. The dosage should be calculated based on body weight
and ... Read more
FDA
Advises Caution With Bisphosphonates
In response to serious postmarketing adverse
reactions, including atypical femur fractures, osteonecrosis of the jaw, and
esophageal cancer, the FDA conducted a systematic review of long-term
bisphosphonate efficacy. This class includes alendronate (Fosamax), etidronate ... Read more
CCSVI
Therapy Alert
The FDA is alerting health care providers and
patients about injuries and death associated with "liberation
therapy" or the "liberation procedure" to treat chronic
cerebrospinal venous insufficiency (CCSVI). CCSVI may cause multiple sclerosis
(MS) or may contribute to the ... Read more
FDA
Reviewing Study of Azithromycin and Cardiovascular Risk
The FDA is reviewing the results of a study
published in the May 17, 2012, issue of the New England Journal of Medicine that compared the risk of
cardiovascular death among patients treated with azithromycin (Zithromax), amoxicillin,
ciprofloxacin (Cipro), levofloxacin (Levaquin), or no antibacterial drug ... Read more
Adderall Counterfeit Product
The FDA is warning consumers and health care
providers about a counterfeit version of Teva Pharmaceutical Industries' Adderall 30 mg
tablets, which contain the wrong active ingredient. Adderall's 4
active ingredients are dextroamphetamine saccharate, amphetamine aspartate,
dextroamphetamine sulfate, and amphetamine sulfate. The counterfeit product
contains tramadol ... Read more
Hospira Carpuject Prefilled Cartridges Alert
The FDA is alerting health care providers of a
potential safety risk with as many as 280 lots of 15 differentCarpuject prefilled cartridges that may be
overfilled by at least twice the expected amount, which may result in overdose.
The company has identified the cause as a manufacturing ... Read more
FDA
Issues Safety Alert for Reumofan Plus
The FDA is warning consumers that Riger Naturals' Reumofan Plus, marketed as a "natural" dietary
supplement for pain relief and other serious conditions, contains several
active ingredients not listed on the label that could be harmful. An FDA
laboratory analysis found that Reumofan ... Read more
Prinzide Black Box Warning Revised
The FDA has approved a revised black box warning
for Prinzide (lisinopril/ hydrochlorothiazide)
tablets noting that the drug can cause injury and death to a developing fetus
and that it should not be used during pregnancy.Prinzide is
indicated for the treatment of hypertension.
FDA
Warns of Seizure Risk with Cefepime
The FDA is reminding health care providers about
the need to adjust the dosage of cefepime in patients with renal impairment.
Cases of nonconvulsive status epilepticus have been associated with the use of
cefepime, primarily in patients with renal impairment who did not receive
appropriate dosage adjustments ... Read more
Nguồn Facts and Comparisons
Nguồn Facts and Comparisons